Dr. Ashley Winslow, CEO/CSO of Odylia Therapeutics, discusses a novel non-profit model for addressing rare diseases and the approaches being designed for two rare genetic eye diseases. Topics include the challenges of developing therapies for rare diseases, the founding of a nonprofit biotech company for rare disease research, gene therapy solutions for eye disorders, and the potential of gene therapy for treating Usher syndrome.